MTP1 Antibody

What is MTF1 and how does it differ from MTP1?

Metal regulatory transcription factor 1 (MTF1) is a 753 amino acid protein containing six C2H2-type zinc finger domains that localizes in the nucleus. It functions as a transcription factor involved in metal regulation pathways . While MTP1 appears to be an iron-export protein expressed in lung cells , MTF1 is distinct as a transcription factor regulating metal-responsive genes. Researchers should carefully verify which protein they're targeting, as the similar nomenclature can cause confusion in experimental design and interpretation.

What are the key specifications I should consider when selecting an MTF1 antibody?

When selecting an MTF1 antibody, consider these critical specifications:

The discrepancy between calculated and observed molecular weights is particularly important for western blot validation .

How do I distinguish between antibodies for MTF1, MTP1, and MT1-MMP in research applications?

Distinguishing between these antibodies requires careful consideration of several factors:

• Target verification: MTF1 (Metal-regulatory Transcription Factor 1) functions as a transcription factor , while MT1-MMP (Membrane Type 1-Matrix Metalloproteinase) is a membrane-bound protease involved in cancer cell migration . MTP1 is an iron-export protein .

• Molecular weight: MTF1 appears at 65-70 kDa in Western blots , while MT1-MMP has a different molecular weight profile.

• Subcellular localization: MTF1 localizes to the nucleus , MT1-MMP is membrane-associated , and MTP1 likely has distinct localization patterns related to iron transport.

• Functional assays: Use metal response element assays for MTF1, matrix degradation assays for MT1-MMP, and iron transport assays for MTP1.

What are the optimal conditions for using MTF1 antibody in Western blot applications?

For optimal Western blot results with MTF1 antibody:

• Sample preparation: MTF1 has been successfully detected in multiple tissue types including mouse liver, brain, heart, and skeletal muscle, as well as Jurkat cells .

• Dilution: Use 1:500-1:2000 dilution range, optimizing for your specific sample type .

• Expected molecular weight: Look for bands at 65-70 kDa, not at the calculated 81 kDa .

• Loading control: Standard loading controls like β-actin or GAPDH are compatible.

• Blocking: Standard blocking protocols with 5% non-fat milk or BSA are typically sufficient.

• Detection system: Both chemiluminescence and fluorescence-based systems are compatible.

Titrate the antibody concentration in your specific experimental system to obtain optimal signal-to-noise ratio .

How should I optimize immunohistochemistry protocols for MTF1 detection?

For IHC optimization with MTF1 antibody:

• Dilution range: 1:50-1:500, requiring optimization for specific tissues .

• Antigen retrieval: Use TE buffer pH 9.0 as the primary method, with citrate buffer pH 6.0 as an alternative .

• Positive control: Human liver tissue has been validated for positive MTF1 detection .

• Visualization system: Both DAB and fluorescence-based detection systems are compatible.

• Counterstaining: Standard hematoxylin counterstaining is appropriate.

• Signal amplification: Consider tyramide signal amplification for low expression samples.

Proper controls should include primary antibody omission and isotype controls to confirm specificity .

What validation approaches should I implement when using MTF1 antibody in new experimental systems?

When validating MTF1 antibody in new systems:

• Positive controls: Use validated tissues (mouse liver, Jurkat cells) .

• Knockdown/knockout validation: Multiple publications have used KD/KO approaches (5 publications cited) .

• Cross-reactivity testing: Test in multiple species if working across species boundaries.

• Peptide competition: Pre-incubate with immunizing peptide to confirm specificity.

• Multiple applications: Verify results using complementary techniques (WB, IHC, IF).

• Multiple antibodies: When possible, confirm findings with antibodies targeting different epitopes.

The antibody has been cited in 25 WB, 4 IHC, 3 IF, 1 IP, and 5 ChIP publications, indicating broad application potential .

What are common issues with MTF1 antibody Western blots and how can I resolve them?

Common issues and solutions for MTF1 Western blotting include:

• Incorrect molecular weight detection:

  • Expected range is 65-70 kDa, not the calculated 81 kDa

  • Ensure complete denaturation of samples

  • Verify gel percentage is appropriate (8-10% typically works well)

• Multiple bands:

  • May indicate post-translational modifications or proteolytic cleavage

  • Verify sample preparation includes protease inhibitors

  • Test antibody specificity using knockdown controls

• Weak or no signal:

  • Increase antibody concentration (try 1:500 if higher dilutions fail)

  • Extend incubation time or optimize antigen retrieval

  • Ensure target is expressed in your sample type

• High background:

  • Increase washing steps

  • Optimize blocking conditions

  • Further dilute antibody

How can I optimize ChIP protocols using MTF1 antibody?

For ChIP optimization with MTF1 antibody:

• Fixation: Standard 1% formaldehyde for 10 minutes typically works for transcription factors.

• Sonication: Optimize to achieve 200-500 bp fragments.

• Antibody amount: Start with 2-5 μg per ChIP reaction based on cited ChIP applications .

• Controls:

  • Input chromatin (pre-IP)

  • IgG control

  • Positive control loci (known MTF1 binding sites)

• Validation: qPCR for known target genes before proceeding to sequencing.

• Analysis focus: Enrichment at metal response elements and other MTF1 binding motifs.

Five publications have successfully used this antibody for ChIP applications, demonstrating its suitability for this technique .

What storage and handling practices maximize MTF1 antibody performance?

To maintain optimal MTF1 antibody performance:

• Storage temperature: Store at -20°C .

• Buffer composition: Supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 .

• Stability: Stable for one year after shipment when properly stored .

• Aliquoting: Not necessary for -20°C storage, minimizing freeze-thaw cycles .

• Working solutions: Prepare fresh dilutions for each experiment.

• BSA content: 20μl sizes contain 0.1% BSA .

Avoid repeated freeze-thaw cycles and exposure to light when using fluorescently conjugated secondary antibodies.

How can MTF1 antibody be used to study metal-regulated transcriptional responses?

The MTF1 antibody enables several approaches to study metal-regulated transcription:

• Expression analysis: Western blot to quantify MTF1 protein levels in response to metal exposure .

• Subcellular localization: Immunofluorescence to track nuclear translocation following metal stimulation.

• Chromatin binding: ChIP to identify metal-dependent MTF1 binding sites genome-wide .

• Protein interactions: Immunoprecipitation to identify cofactors involved in metal sensing.

• Tissue specificity: IHC to analyze expression patterns across different metal-exposed tissues .

Research confirms MTF1 is expressed in multiple tissues including liver, brain, heart, and skeletal muscle, suggesting diverse roles in systemic metal homeostasis .

What are the comparative advantages of using MT1-MMP antibodies versus MTF1 antibodies in cancer research?

When designing cancer research studies, consider these distinct applications:

MT1-MMP antibodies:

• Target a key protease in cancer cell migration and invasion

• Useful for studying extracellular matrix degradation

• Can potentially inhibit cancer cell invasion (e.g., 3A2 antibody)

• Important for analyzing metastatic processes in melanoma and other cancers

MTF1 antibodies:

• Target a transcription factor involved in metal homeostasis

• Useful for studying metal-regulated gene expression in cancer cells

• Can reveal stress responses in tumor microenvironments

• Help understand metallothionein regulation in chemoresistance

Choose based on whether you're investigating proteolytic aspects of invasion (MT1-MMP) or metal-regulated gene expression (MTF1) in your cancer model.

How might researchers apply MTF1/MTP1 antibodies in studies of iron metabolism disorders?

For iron metabolism disorder research:

MTP1 studies (iron-export protein):

• Investigate expression changes in iron overload or deficiency conditions

• Analyze tissue-specific regulation, particularly in lung cells

• Study relationship between iron levels and transporter expression

MTF1 studies (metal-regulatory transcription factor):

• Examine transcriptional responses to altered iron status

• Analyze cross-talk between different metal regulatory pathways

• Investigate metal-responsive gene networks in iron disorders

Combined approaches could reveal how iron transport systems (MTP1) and their transcriptional regulation (potentially by MTF1) are coordinated in disease states, providing insights for therapeutic targeting.

How should I interpret discrepancies between calculated and observed molecular weights for MTF1?

The MTF1 protein shows a consistent discrepancy between its calculated molecular weight (81 kDa) and observed Western blot bands (65-70 kDa) . When interpreting such discrepancies:

• Potential explanations:

  • Post-translational modifications altering mobility

  • Alternative splicing yielding shorter isoforms

  • Proteolytic processing of the full-length protein

  • Aberrant migration due to protein structure or charge

• Validation approaches:

  • Verify with multiple antibodies targeting different epitopes

  • Confirm with mass spectrometry analysis

  • Test in knockout/knockdown systems

  • Compare migration patterns across different cell/tissue types

This discrepancy is consistently observed and documented by the manufacturer, suggesting it represents a genuine biological phenomenon rather than an artifact .

What is the significance of MTF1 expression across different tissue types?

MTF1 expression has been detected across diverse tissues with potential functional implications:

This broad expression pattern suggests MTF1 mediates essential metal regulatory functions across multiple physiological systems rather than being tissue-restricted .

How do the available research tools for studying MTF1 compare to those for MT1-MMP in functional studies?

Current research tools for these proteins have distinct strengths and applications:

MTF1 research tools:

• Commercial antibodies validated for multiple applications (WB, IHC, IF, IP, ChIP)

• Primarily detection-oriented rather than function-blocking

• Well-characterized in diverse tissues and species

• Suitable for transcriptional regulation studies

MT1-MMP research tools:

• Function-blocking antibodies available (e.g., 3A2)

• Demonstrated efficacy in inhibiting cancer cell invasion

• Important for therapeutic development approaches

• Designed for targeting proteolytic activities

MTF1 tools are currently more focused on detection and characterization, while MT1-MMP research has advanced to developing function-blocking antibodies with therapeutic potential .